Increased Prevalence of Tricuspid Regurgitation in Patients with Prolactinomas Chronically Treated with Cabergoline | Zendy

Annamaria Colao | Zendy; Maurizio Galderisi | Zendy; Antonella Di Sarno | Zendy; M. Pardo | Zendy; Maria Gaccione | Zendy; Marianna D’Andrea | Zendy; Ermelinda Guerra | Zendy; Rosario Pivonello | Zendy; Giuseppe Lerro | Zendy; Gaetano Lombardi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increased Prevalence of Tricuspid Regurgitation in Patients with Prolactinomas Chronically Treated with Cabergoline

Author(s) -

Annamaria Colao,

Maurizio Galderisi,

Antonella Di Sarno,

M. Pardo,

Maria Gaccione,

Marianna D’Andrea,

Ermelinda Guerra,

Rosario Pivonello,

Giuseppe Lerro,

Gaetano Lombardi

Publication year - 2008

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2007-1403

Subject(s) - cabergoline , medicine , dopamine agonist , regurgitation (circulation) , gastroenterology , cumulative dose , cardiology , surgery , endocrinology , agonist , hormone , receptor , prolactin

Cabergoline, a dopamine receptor-2 agonist used to treat prolactinomas, was associated with increased risk of cardiac valve disease in Parkinson's disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research